目的 探討丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合甲磺酸酚妥拉明注射液治療肺源性心臟病加重期的臨床療效。方法 選取2016年7月-2017年7月西電集團(tuán)醫(yī)院收治的肺源性心臟病急性加重期患者78例為研究對(duì)象，按照隨機(jī)分組設(shè)計(jì)將研究對(duì)象分為對(duì)照組和治療組，每組各39例。對(duì)照組靜脈滴注甲磺酸酚妥拉明注射液，20 mg加入到5%葡萄糖注射液250 mL中，1次/d。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注丹參酮Ⅱ_A磺酸鈉注射液，50 mg加入到0.9%氯化鈉溶液250 mL中，1次/d。兩組患者連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的血液流變學(xué)指標(biāo)、心功能指標(biāo)和血?dú)庵笜?biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為74.4%、92.3%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組全血高切黏度、全血低切黏度、血漿黏度、纖維蛋白原、紅細(xì)胞積壓均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左心室射血分?jǐn)?shù)（LVEF）、每搏輸出量（SV）、一氧化碳（CO）均顯著升高，平均肺動(dòng)脈壓（mPVP）均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組動(dòng)脈血氧分壓（pO₂）水平均顯著升高，動(dòng)脈血二氧化碳分壓（pCO₂）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合甲磺酸酚妥拉明注射液治療肺源性心臟病加重期具有較好的臨床療效，可改善心臟功能，改善血液流變學(xué)指標(biāo)和血?dú)庵笜?biāo)，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical effect of Tanshinone Ⅱ_A Sulfonate Sodium Injection combined with Phentolamine Mesylate Injection in treatment of acute exacerbation of pulmonary heart disease. Methods Patients (78 cases) with acute exacerbation of pulmonary heart disease in Xi'an XD Group Hospital from July 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Phentolamine Mesylate Injection, 20 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Tanshinone Ⅱ_A Sulfonate Sodium Injection on the basis of the control group, 50 mg added into normal saline 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and hemorheological indexes, heart function indexes, and blood gas indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.4% and 92.3%, respectively, and there was difference between two groups (P<0.05). After treatment, whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, fibrinogen, and erythrocyte backlog in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVEF, SV, and CO in two groups were significantly increased, but the mPVP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of pO₂ in two groups were significantly increased, but the levels of pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tanshinone Ⅱ_A Sulfonate Sodium Injection combined with Phentolamine Mesylate Injection has clinical curative effect in treatment of acute exacerbation of pulmonary heart disease, can improve heart function, regulate hemorheological index and blood gas index, with good safety, which has a certain clinical application value.